Events

Videos

Podcasts

Articles

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Sequencing Checkpoint Inhibitors in NSCLC

Optimizing Checkpoint Inhibition in NSCLC

Immune Checkpoint Inhibitors in NSCLC

Evolving Renal Cell Carcinoma Treatment Paradigm

Rini Explores PD-1 Inhibition in Renal Cell Carcinoma

Development of Checkpoint Inhibitors for GU Cancers

Checkpoint Inhibition in Renal Cell Carcinoma

Utility of PD-L1 as a Biomarker in Bladder Cancer

Evolving Role of PD-L1 as a Biomarker

PD-L1 Immunotherapy in Bladder Cancer

Targeted Immunotherapy in Cancer

Future Role of Immunotherapy in Cancer

PD-L1 Inhibition With MPDL3280A in Bladder Cancer

Adjuvant Ipilimumab in High-Risk Melanoma

Checkpoint Inhibitor Combination Strategies

Future Role of Checkpoint Inhibitors in Melanoma

Checkpoint Inhibitors in Metastatic Melanoma

Introduction: Immunotherapy Research Milestones

Immunotherapy agents are delivering impressive results in a broad range of tumor types, reinforcing the excitement in research and investment circles for anticancer strategies that actively harness the immune system

Immunotherapy Branches Out

The treatment landscape for patients with non-small cell lung cancer (NSCLC) is poised to undergo dramatic changes, as novel immunotherapies, second-generation targeted therapies, and new maintenance strategies continue to show promise in clinical trials.

Novel Therapies, Strategies in Development for NSCLC

Immuno-Oncology

Immuno-Oncology | Specialty